BRCA1 and ovarian carcinoma: In the SOLO1 trial (NCT01844986), patients with newly diagnosed advanced ovarian cancers were tested for BRCA1/2 mutation by BRACAnalysis (Myriad) or BRCA1/2 genetic testing assay (BGI) before randomization into olaparib and placebo groups as maintenance therapy.